ReTain

The ReTain study will evaluate a new pharmacological therapy for preclinical Alzheimer's. The goal of the study is to investigate the effect of this therapy on cognitive decline.

The clinical trial, led by the pharmaceutical company Janssen-Cilag S.A., is a multicenter study that evaluates the effectiveness, safety and immunogenicity of an active immunotherapy directed at phosphorylated tau, in participants with preclinical Alzheimer's.